Pressmeddelanden från ODI Pharma

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Publication of half-year report 2025/2026 29 dec 2025 15:30

ODI Pharma issues a reverse profit warning following improved revenue development 05 dec 2025 18:45

Notice to Annual General Meeting in ODI Pharma AB (publ)05 dec 2025 18:45

Kommuniké från årsstämma i ODI Pharma AB (publ)27 nov 2025 16:35

Publication of interim report Q1 2025/2026 24 nov 2025 15:15

ODI Pharma demonstrates clear operational progress and improved commercial outlook 21 nov 2025 19:00

ODI Pharma AB publishes the annual report for the fiscal year 2024/2025 21 nov 2025 19:00

ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2024/2025 31 okt 2025 12:10

Notice to Annual General Meeting in ODI Pharma AB (publ)31 okt 2025 12:10

Kallelse till årsstämma i ODI Pharma AB (publ)29 aug 2025 11:22

ODI Pharma publishes financial calendar for 2025 28 aug 2025 18:10

Publication of year-end report Q4 2024/2025 26 jun 2025 15:55

Report from the Extraordinary General Meeting 26 jun 2025 15:55

Stämmokommuniké från extra bolagsstämma i ODI Pharma AB (publ)10 jun 2025 15:00

Kallelse till extra bolagsstämma i ODI Pharma AB (publ)10 jun 2025 15:00

Notice of Extraordinary General Meeting in ODI Pharma AB (publ)09 jun 2025 20:15

ODI Pharma proposes directed share issue of approximately SEK 2.0 million 29 maj 2025 14:00

Publication of interim report Q3 2024/2025 27 feb 2025 17:35

Publication of half-year report 2024/2025 16 jan 2025 11:50

ODI Pharma terminates the agreement with liquidity provider 30 dec 2024 11:59

Kommuniké från årsstämma i ODI Pharma AB (publ)30 dec 2024 11:59

Announcement from the Annual General Meeting in ODI Pharma AB (publ)19 dec 2024 13:30

ODI Pharma AB announces last day of trading in BTA 13 dec 2024 11:30

Flagging notification 11 dec 2024 15:55

ODI Pharma AB publishes outcome of rights issue 04 dec 2024 13:30

ODI Pharma achieved market share targets in 2024 and increases its targets for 2025. Positioned for growth as Poland's medical cannabis market expands.02 dec 2024 07:45

ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2023/2024 02 dec 2024 07:45

ODI Pharma AB publishes the annual report for the fiscal year 2023/2024 27 nov 2024 11:30

Kallelse till årsstämma i ODI Pharma AB (publ)27 nov 2024 11:30

Notice to Annual General Meeting in ODI Pharma AB (publ)26 nov 2024 07:50

The subscription period in ODI Pharma AB’s preferential rights issue commences today 25 nov 2024 11:45

ODI Pharma AB publishes memorandum prior to preferential rights issue 22 nov 2024 15:31

Publication of interim report Q1 2024/2025 22 nov 2024 15:30

ODI Pharma moves the AGM and postpones the publication of Annual Report 2023/2024 19 nov 2024 16:00

Report from the Extraordinary General Meeting on 19 November in ODI Pharma AB (publ)19 nov 2024 16:00

Kommuniké från extra bolagsstämma den 19 november i ODI Pharma AB (publ)13 nov 2024 12:30

Uppdaterad kallelse till årsstämma i ODI Pharma AB (publ)13 nov 2024 12:30

Updated Notice of Annual General Meeting in ODI Pharma AB (publ)12 nov 2024 11:41

ODI Pharma appoints new CEO 12 nov 2024 11:40

Notice to Annual General Meeting in ODI Pharma AB (publ)12 nov 2024 11:40

Kallelse till årsstämma i ODI Pharma AB (publ)30 okt 2024 15:42

Notice of Extraordinary General Meeting in ODI Pharma AB (publ)30 okt 2024 15:42

Kallelse till extra bolagsstämma i ODI Pharma AB (publ)30 okt 2024 15:41

Proposal for change in the Board of Directors of ODI Pharma AB 30 okt 2024 15:40

ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report 25 jun 2024 18:35

ODI Pharma AB announces strategic market entry with initial shipment to Switzerland 30 maj 2024 11:45

ODI Pharma AB: Publication of interim report Q3 2023/2024 02 maj 2024 13:30

Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024 15 dec 2023 11:15

Announcement from the Annual General Meeting in ODI Pharma AB (publ)15 dec 2023 11:15

Kommuniké från årsstämma i ODI Pharma AB (publ)06 dec 2023 13:53

ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek 27 nov 2023 13:17

Correction: ODI Pharma AB publishes the annual report for the fiscal year 2022/2023 27 nov 2023 13:17

Rättelse: ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2022/2023 24 nov 2023 17:45

ODI Pharma AB publicerar årsredovisning för räkenskapsåret 2022/2023 24 nov 2023 17:45

ODI Pharma AB publishes the annual report for the fiscal year 2022/2023 23 nov 2023 19:45

ODI Pharma AB postpones publication of interim report and annual report until November 24, 2023 13 nov 2023 14:35

Notice to Annual General Meeting in ODI Pharma AB (publ)13 nov 2023 14:35

Kallelse till årsstämma i ODI Pharma AB (publ)24 aug 2023 19:00

ODI Pharma AB: Publication of year-end report for the fiscal year 2022/2023 07 aug 2023 11:00

ODI Pharma AB enters into exclusive collaboration with Synoptis Pharma Sp. z o.o.01 jun 2023 10:44

ODI Pharma AB receives loan financing of EUR 350,000 25 maj 2023 18:06

ODI Pharma AB: Publication of interim report report Q3 2022/2023 23 feb 2023 17:47

ODI Pharma AB: Publication of half-year report 2022/2023 24 jan 2023 13:57

ODI Pharma receives approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market 15 nov 2022 10:12

Notice to Annual General Meeting in ODI Pharma AB (publ)15 nov 2022 10:12

Kallelse till årsstämma i ODI Pharma AB (publ)25 aug 2022 19:00

ODI Pharma AB: Publication of year-end report for the fiscal year 2021/2022 25 feb 2022 21:33

Correction: ODI Pharma AB: Publication of half-year report 2021 24 feb 2022 19:47

ODI Pharma AB: Publication of half-year report 2021 13 dec 2021 11:19

Announcement from the Annual General Meeting in ODI Pharma AB (publ)13 dec 2021 11:13

Kommuniké från årsstämma i ODI Pharma AB (publ)25 nov 2021 17:10

ODI Pharma AB: Publication of interim report for the first quarter 2021/2022 18 nov 2021 16:18

ODI Pharma AB publishes the annual report for the fiscal year 2020/2021 09 nov 2021 16:20

Kallelse till årsstämma i ODI Pharma AB (publ)09 nov 2021 16:20

Notice to Annual General Meeting in ODI Pharma AB (publ)28 sep 2021 14:43

ODI Pharma AB announces the date of official launch of kandol.26 aug 2021 18:26

ODI Pharma AB: Publication of year-end report for the financial year 2020/2021 17 aug 2021 18:07

ODI Pharma AB approves the official launch of kandol., an exclusive CBD infused skincare line 09 jul 2021 16:24

ODI Pharma AB: Flagging notification 27 maj 2021 18:23

ODI Pharma AB: Publication of interim report for the third quarter 2020/2021 21 apr 2021 18:38

ODI Pharma: Update on progress in “Project Poland” and “Project Skin”25 feb 2021 15:15

ODI Pharma AB: Publication of half-year report 2020 14 dec 2020 12:23

Kommuniké från årsstämma i ODI Pharma AB (publ)19 nov 2020 12:15

ODI Pharma AB publishes the annual report for the fiscal year 2019/2020 11 nov 2020 13:35

Kallelse till årsstämma i ODI Pharma AB (publ)27 aug 2020 18:33

ODI Pharma AB: Publication of year-end report 23 jan 2020 08:30

Idag inleds handeln i ODI Pharmas aktier på Spotlight Stock Market 20 jan 2020 15:08

Slutlig registrering av ODI Pharmas nyemission genomförd 20 jan 2020 12:23

Korrigering-Delregistrering av ODI Pharmas nyemission genomförd 20 jan 2020 11:11

Delregistrering av ODI Pharmas nyemission genomförd 03 jan 2020 10:23

ODI Pharmas nyemission inför notering kraftigt övertecknad 16 dec 2019 09:55

ODI Pharma har godkänts för notering på Spotlight Stock Market – idag inleds teckningstiden i nyemissionen